74PPhase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). (17th December 2018) - Babiker, H M; Brana, I; Mahadevan, D; Owonikoko, T K; Calvo, E; Rischin, D; Moreno, V; Papadopoulos, K P; Crittenden, M; Formenti, S; Giralt, J; Garrido, P; et al.